BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29946240)

  • 1. Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington's Disease.
    Jang M; Lee SE; Cho IH
    Front Cell Neurosci; 2018; 12():157. PubMed ID: 29946240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors.
    Jang M; Choi JH; Chang Y; Lee SJ; Nah SY; Cho IH
    Brain Behav Immun; 2019 Aug; 80():146-162. PubMed ID: 30853569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.
    Pitzer M; Lueras J; Warden A; Weber S; McBride J
    Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
    Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression.
    Niu L; Zhou Y; Wang J; Zeng W
    Metab Brain Dis; 2024 Apr; 39(4):559-567. PubMed ID: 38261161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington's disease.
    Niu L; Ye C; Sun Y; Peng T; Yang S; Wang W; Li H
    Cell Biosci; 2018; 8():41. PubMed ID: 30002810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
    Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
    Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebulization of low-dose aspirin ameliorates Huntington's pathology in N171-82Q transgenic mice.
    Mondal S; Prieto S; Rangasamy SB; Dutta D; Pahan K
    NeuroImmune Pharm Ther; 2024 Mar; 3(1):47-59. PubMed ID: 38532785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
    Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
    Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
    Southwell AL; Ko J; Patterson PH
    J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease.
    So KH; Choi JH; Islam J; Kc E; Moon HC; Won SY; Kim HK; Kim S; Hyun SH; Park YS
    J Korean Neurosurg Soc; 2020 Sep; 63(5):579-589. PubMed ID: 32131152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
    Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
    J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.